Dr Reddy's Lt
A global, vertically integrated pharmaceutical company with a presence in APIs, branded formulations, generics, biologics, speciality products and NCEs, marketed in over 100 countries with an emphasis on North America, Europe, India, Russia and other emerging markets. Dr Reddy's is pursuing low-cost innovation in NCE and proprietary products with a focus on US dermatology and neurology segments. The company formulated Rituximab, the world's first monocolonal antibody, and is actively engaged in developing and launching biosimilars. It has an alliance with Merck Serono.